US 12,357,637 B2
Solid pharmaceutical composition comprising TLR7 agonist
Jianghui Jing, Lianyungang (CN); Lihui Dong, Lianyungang (CN); Yi Xu, Lianyungang (CN); Xinlu Li, Lianyungang (CN); Xifeng Lu, Lianyungang (CN); Shang Wang, Lianyungang (CN); Haishan Zang, Lianyungang (CN); Min Li, Lianyungang (CN); Zhilin Chen, Lianyungang (CN); Xiandong Zhao, Lianyungang (CN); and Peng Sun, Lianyungang (CN)
Assigned to Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang (CN)
Appl. No. 17/594,439
Filed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang (CN)
PCT Filed Apr. 23, 2020, PCT No. PCT/CN2020/086301
§ 371(c)(1), (2) Date Oct. 15, 2021,
PCT Pub. No. WO2020/216274, PCT Pub. Date Oct. 29, 2020.
Claims priority of application No. 201910326899.9 (CN), filed on Apr. 23, 2019.
Prior Publication US 2022/0184085 A1, Jun. 16, 2022
Int. Cl. A61K 31/519 (2006.01); A61K 9/20 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2095 (2013.01)] 15 Claims
 
1. A solid pharmaceutical composition, comprising a compound of formula I, a diluent, a binder, a disintegrant, and a lubricant,

OG Complex Work Unit Chemistry
wherein:
the diluent is selected from the group consisting of microcrystalline cellulose, pregelatinized starch, and a mixture thereof;
the disintegrant is sodium carboxymethyl starch;
the binder is hydroxypropyl methylcellulose; and
the lubricant is selected from the group consisting of magnesium stearate, colloidal silicon dioxide, and a mixture thereof;
wherein the solid pharmaceutical composition is prepared by a direct compression method.